• Our founder: Albert Boehringer (1861 - 1939), Counsellor of Commerce, in 1910.
• Albert Boehringer was the grandson of Christian Friedrich Boehringer who had started the family's chemical business in Stuttgart in 1817.

• 1885: First chemical factory in Ingelheim is set up
• 1895: Pioneer of large-scale "biotech" production. Boehringer's company was already establishing a reputation for social enlightenment and for technologically innovative products
• 1902: First health insurance scheme is founded
• 1909: Boehringer products appear in pharmacies
• 1910: Introduction of annual holiday for employees
• 1912: Company pension made available to employees with >20 years of service

• 1955: Introduction of new and highly effective drugs

• 1971: USA subsidiary founded in Ridgefield, Connecticut
• 1972: Boehringer Ingelheim (Canada) Ltd./Ltée founded in Montréal, Québec
• 1980: Modern era of biotechnology dawns. Again, Boehringer Ingelheim takes a pioneering role in biotechnology and collaborates with leading-edge companies such as Genentech, IDEC, NeoRx and ISIS
• 1981: Take-over of Roxane Laboratories in Columbus, Ohio
• 1986: Germany's first biotechnological production plant is founded
• 1987: Boehringer Ingelheim's first genetically engineered product and the first result of a strategic collaboration with Genentech, Inc.

• 1992: The first Board of Managing Directors is formed to meet the needs of the fast-changing business environment
• 1994: Our guiding principles are set committing Boehringer Ingelheim to ambitious, long-term, entrepreneurial goals. "Value through Innovation" has guided us for more than ten years and will continue to do so. "Lead and Learn" is the current phase in our evolution in how we want to work together

• Boehringer Ingelheim has become one of the most successful non-domestic companies operating in the USA and Japan
• Our R&D has been transformed through pioneering new technologies, such as high throughput and ultrahigh  throughput screening
• Our Human Pharmaceuticals business was extended with the acquisition of the injectables manufacturer Ben Venue Laboratories (USA)
• Our manufacturing structure has been transformed and the logistics chain overhauled
• New alliances have been formed with other leading companies, such as Genentech, Abbott Laboratories, Pfizer Inc., Lilly and Company, Biolipox, AbGenomics and others

Boehringer Ingelheim (Canada) Ltd./Ltée is founded in Montréal, Québec.

Boehringer Ingelheim (Canada) Ltd./Ltée moves its headquarters from Montreal, Québec to Burlington, Ontario.

Boehringer Ingelheim establishes the Animal Health Division specializing in bovine and equine products.

Boehringer Ingelheim (Canada) Ltd./Ltée purchases Bio-Méga research facility in Laval, Québec

Boehringer Ingelheim (Canada) Ltd./Ltée acquires Quest Vitamins of Vancouver, British Columbia, which became a part of the Self-Medication Business Unit

Boehringer Ingelheim (Canada) Ltd./Ltée Research and Development Centre in Laval, Québec undergoes its first expansion

Boehringer Ingelheim (Canada) Ltd./Ltée celebrates 30 years in Canada, Quest Vitamins is sold to PanGeo.

Boehringer Ingelheim Research and Development Centre in Laval, Québec completes a $36 million investment to facilitate 40 high-calibre scientists to join an existing team of 150 researchers

Boehringer Ingelheim (Canada) Ltd./Ltée employs over 700 people across Canada with headquarters operating in Burlington, Ontario and a major Research and Development facility in Laval, Québec. The two main areas of business are Human Prescription Pharmaceuticals and Animal Health